Paul Ehrlich's magic bullet concept: 100 years of progress - PubMed

Affiliations

• PMID: 18469827
• DOI: 10.1038/nrc2394

Review

Paul Ehrlich's magic bullet concept: 100 years of progress

Klaus Strebhardt et al. Nat Rev Cancer. 2008 Jun.

Abstract

Exceptional advances in molecular biology and genetic research have expedited cancer drug development tremendously. The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific molecular defects of a cancer patient. It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clinical success. One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiology or Medicine. His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful molecular cancer therapeutics.

Similar articles

• The impact of molecular targets in cancer drug development: major hurdles and future strategies.

  Hebar A, Valent P, Selzer E. Hebar A, et al. Expert Rev Clin Pharmacol. 2013 Jan;6(1):23-34. doi: 10.1586/ecp.12.71. Expert Rev Clin Pharmacol. 2013. PMID: 23272790

• The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize.

  Bosch F, Rosich L. Bosch F, et al. Pharmacology. 2008;82(3):171-9. doi: 10.1159/000149583. Epub 2008 Aug 5. Pharmacology. 2008. PMID: 18679046 Free PMC article. Review.

• [100 years of Dr. Ehrlich's magic bullet (1909-2009)].

  García-Sánchez JE, García E, Merino ML. García-Sánchez JE, et al. Enferm Infecc Microbiol Clin. 2010 Oct;28(8):521-33. doi: 10.1016/j.eimc.2009.07.009. Epub 2010 Jan 25. Enferm Infecc Microbiol Clin. 2010. PMID: 20097455 Review. Spanish.

• Ilya Ilich Metchnikoff (1845-1915) and Paul Ehrlich (1854-1915): the centennial of the 1908 Nobel Prize in Physiology or Medicine.

  Schmalstieg FC Jr, Goldman AS. Schmalstieg FC Jr, et al. J Med Biogr. 2008 May;16(2):96-103. doi: 10.1258/jmb.2008.008006. J Med Biogr. 2008. PMID: 18463079

Cited by

• A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.

  Kesireddy M, Kothapalli SR, Gundepalli SG, Asif S. Kesireddy M, et al. Pharmaceut Med. 2024 Jan;38(1):39-54. doi: 10.1007/s40290-023-00505-8. Epub 2023 Nov 29. Pharmaceut Med. 2024. PMID: 38019416 Review.

• Targeting CDK9 for Anti-Cancer Therapeutics.

  Mandal R, Becker S, Strebhardt K. Mandal R, et al. Cancers (Basel). 2021 May 1;13(9):2181. doi: 10.3390/cancers13092181. Cancers (Basel). 2021. PMID: 34062779 Free PMC article. Review.

• Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.

  Hamamichi S, Fukuhara T, Hattori N. Hamamichi S, et al. Toxins (Basel). 2020 Oct 15;12(10):658. doi: 10.3390/toxins12100658. Toxins (Basel). 2020. PMID: 33076544 Free PMC article. Review.

• Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.

  Della Cristina P, Castagna M, Lombardi A, Barison E, Tagliabue G, Ceriotti A, Koutris I, Di Leandro L, Giansanti F, Vago R, Ippoliti R, Flavell SU, Flavell DJ, Colombatti M, Fabbrini MS. Della Cristina P, et al. Microb Cell Fact. 2015 Feb 13;14:19. doi: 10.1186/s12934-015-0202-z. Microb Cell Fact. 2015. PMID: 25889802 Free PMC article.

• Recent strides in macromolecular targeted photodynamic therapy for cancer.

  Quaye MB, Obaid G. Quaye MB, et al. Curr Opin Chem Biol. 2024 Aug;81:102497. doi: 10.1016/j.cbpa.2024.102497. Epub 2024 Jul 5. Curr Opin Chem Biol. 2024. PMID: 38971130 Review.

Publication types

MeSH terms

Substances

Personal name as subject

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database